BiosyentTSXV:RX +0.86%99 FCF Margin % is 19.36% as of Mar. 2026, which is 4% above its 10-year median of 18.57. GuruFocus rates TSXV:RX with a GF Score™ of 99/100 and a GF Value™ of C$16.11 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 958 Drug Manufacturers companies, Biosyent ranks better than 94.47% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biosyent's Free Cash Flow for the
three
months ended in Mar. 2026 was C$2.69 Mil. Biosyent's Revenue for the
three
months ended in Mar. 2026 was C$13.91 Mil. Therefore, Biosyent's FCF Margin % for the quarter that ended in Mar. 2026 was 19.36%.
The historical rank and industry rank for Biosyent's FCF Margin % or its related term are showing as below:
TSXV:RX'
s FCF Margin % Range Over the Past 10 Years
Min: 11.4 Med: 18.57 Max: 30.09
Current: 26.36
During the past 13 years, the highest FCF Margin % of Biosyent was 30.09%. The lowest was 11.40%. And the median was 18.57%.
TSXV:RX's FCF Margin % is ranked better than 94.47% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs TSXV:RX: 26.36
Biosyent FCF Margin % Related Terms
Biosyent FCF Margin % Historical Data
* Premium members only.
The historical data trend for Biosyent's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biosyent's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent (TSXV:RX) has a FCF Margin % of 19.36% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biosyent and its competitors. This is near median its historical median of 18.57. Over the past decade, Biosyent's FCF Margin % has ranged from 11.40 to 30.09. According to the industry distribution chart, Biosyent ranks #53 out of 958 companies in the Drug Manufacturers industry, placing it in the top 5.5%.
Is Biosyent's FCF Margin % too high?
Biosyent's current FCF Margin % of 19.36% is near median its 10-year median of 18.57. Over the past 10 years, this metric has ranged from a low of 11.40 to a high of 30.09. The Drug Manufacturers industry median FCF Margin % is 2.45. Biosyent's value of 19.36% is 691.8% above this industry median. Based on the distribution chart, Biosyent ranks #53 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biosyent has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #53 out of 958 companies for FCF Margin %. This places Biosyent in the top 6% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Biosyent's value of 19.36% is 691.8% above this benchmark. Historically, Biosyent's own FCF Margin % has ranged from 11.40 to 30.09 over the past decade. While the company's 10-year median is 18.57 vs. the industry median of 2.45, Biosyent has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current FCF Margin % of 19.36% is 691.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current FCF Margin % is 19.36%, which is near median its own 10-year median of 18.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (TSXV:RX) is currently considered Modestly Undervalued. The stock's GF Value™ is C$16.11, compared to a current price of C$14.05 — trading 12.8% below its estimated fair value. The current FCF Margin % is 19.36%, which is near median its 10-year median of 18.57 and 691.8% above the Drug Manufacturers industry median of 2.45. Biosyent's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biosyent (TSXV:RX), the current FCF Margin % is 19.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (TSXV:RX) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of C$14.05 is trading 12.8% below its estimated GF Value™ of C$16.11.
GuruFocus considers Biosyent to be Modestly Undervalued.
Key valuation signals for TSXV:RX:
FCF Margin %: 19.36% (near median its 10-year median of 18.57)
GF Value™: C$16.11 vs. price of C$14.05 (12.8% below fair value)
Industry Position: 691.8% above the Drug Manufacturers median (#53 of 958)
No single metric tells the full story. See the TSXV:RX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
99GF Score
Get the complete analysis for TSXV:RX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:RX has been successfully added to your 
